As a NAT10 inhibitor, remodelin has been shown to significantly affect cancer cells’ mitochondrial lipid metabolism through various intricate pathways, thereby altering the cells’ susceptibility to different chemotherapeutic drugs [38, 45]. Here, NAT10 is linked to cancer.